Skip to main content
. Author manuscript; available in PMC: 2022 Apr 26.
Published in final edited form as: Annu Rev Immunol. 2021 Feb 12;39:537–556. doi: 10.1146/annurev-immunol-101819-092536

Table 1b:

Anti-tumor roles of IL-17

Species Cancer Type Mechanism/s
Human Cervical adenocarcinoma Increased number of IL-17+ cells in patients were significantly correlated with the absence of vaso-invasion, less infiltration depths and smaller tumor growths. (117)
Mouse fibrosarcoma IL-17-overexpresssion drives upregulation of MHC I and II, thereby making fibrosarcoma cells increasingly susceptible to anti-tumor T cells. (118)
Human Esophageal cancer IL-17 drives chemokine production from the tumors, leading to the infiltration of cytotoxic neutrophils, CD8+CTLs and dendritic cells resulting in better tumor control and patient survival. (119, 120)
Mouse Lung Cancer IL-17 controls tumor growth and metastasis by enhancing the cytotoxic potential of anti-tumor CD8+ T cells (121), and by increasing IFN-γ production from anti-tumor T cells and NK cells. (122)
Mouse Breast Cancer IL-17 inhibits the accumulation of MDSCs in tumor microenvironment by suppressing their proliferation and triggering apoptosis. (123)
Human Colorectal cancer Individuals with higher IL-17 expression exhibited better disease control and survival which is linked to increased infiltration of cytotoxic CD15+ neutrophils (124).